Recent publications published by researchers at the MRC WIMM.
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AML.
Wang Z. et al, (2025), Blood
Molecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.
Godfrey AL. et al, (2024), Br J Haematol
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.
Carrelha J. et al, (2024), Nat Immunol, 25, 1007 - 1019
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT. et al, (2024), Blood Adv
Backtracking to the future: unraveling the origins of childhood leukemia.
de Smith AJ. et al, (2024), Leukemia, 38, 416 - 419
Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
Oh ST. et al, (2024), EJHaem, 5, 105 - 116
Erythroid Differentiation Enhances RNA Mis-Splicing in SF3B1-Mutant Myelodysplastic Syndromes with Ring Sideroblasts.
Moura PL. et al, (2024), Cancer Res, 84, 211 - 225
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Rampotas A. et al, (2024), Blood, 143, 178 - 182
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2024), Br J Haematol, 204, 127 - 135
Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML
Wang Z. et al, (2024), BLOOD, 144, 2749 - 2751
Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies
Wong ZC. et al, (2024), CANCER RESEARCH, 84
Interim Analysis of Promise, a Clinical Study Combining the BET Inhibitor OPN-2853 with Ruxolitinib in Patients with Advanced Myelofibrosis Experiencing an Inadequate Response to Ruxolitinib
Mead AJ. et al, (2024), BLOOD, 144, 3186 - 3187
Real World Efficacy and Safety of Momelotinib for Myelofibrosis: Evaluation of a UK-Wide Study Confirms 40% Anaemia Response Rate in a Non-Clinical Trial Cohort
Rampotas A. et al, (2024), BLOOD, 144, 1804 - 1806
Single-Cell Multiomic Profiling of TP53 Mutated Myelodysplastic Neoplasms- All Clones Are Not Equal
Chowdhury O. et al, (2024), BLOOD, 144, 3615 - 3616
Spatial Transcriptomics Identifies Aberrant Communication between Dendritic Cells and Leukemia Stem Cells As a Therapeutically Targetable Axis in Juvenile Myelomonocytic Leukemia
Louka E. et al, (2024), BLOOD, 144, 822 - 823
The management of myelofibrosis: A British Society for Haematology Guideline.
McLornan DP. et al, (2024), Br J Haematol, 204, 136 - 150
Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of DYRK1A.
Brierley CK. et al, (2023), bioRxiv